A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma
← catalyst calendarSponsored by Jasper Therapeutics, Inc. (industry) · JSPR — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
17actual
Sites
6
Country
Canada
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision - terminated due to changes in company priorities and not related to safety concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-26 | actual | When the study began enrolling |
| Primary completion | 2025-08-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-11 | actual | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Allergic Asthma
Interventions
- Drug: Briquilimab — also filed as JSP191
- Other: Placebo Comparator
Primary outcomes
what the primary-completion date above is the date OFTo evaluate the safety and tolerability of briquilimab in mild-to-moderate asthmatic participants
measured From signing the informed consent form (ICF) through end of trial (EOT) visit (up to 4.5 months)
To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR
measured 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
To compare the effect of treatment with briquilimab vs placebo on the allergen-induced LAR
measured 3-7 hours after allergen challenge between Briquilimab and Placebo at week 6
Permalink · JSPR's whole pipeline · Catalyst calendar · Every registered study · What changed